STOCK TITAN

Enanta Pharmaceuticals Inc - ENTA STOCK NEWS

Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.

Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.

Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.

Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that data from their Phase 2a human challenge study of EDP-323, a first-in-class oral RSV treatment, will be presented at ESCMID Global 2025 in Vienna, Austria. The presentation will showcase results from the study, which were initially announced in September 2024, including new data on respiratory mucus production.

EDP-323 is a non-nucleoside small-molecule inhibitor targeting the RSV polymerase (L-protein). The ePoster presentation, titled 'EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study,' will be presented by Dr. John P. DeVincenzo on April 13, 2025, at 8:30 a.m. CEST.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
none
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications, has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.

The management team will deliver their presentation on Thursday, March 27, 2025, at 11:00 a.m. ET. Interested parties can access the live webcast through the 'Events and Presentations' section on the 'Investors' page of Enanta's website. A replay will be available post-presentation and remain accessible for a minimum of 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
conferences
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its upcoming presentations at the 13th International RSV Symposium (RSV 2025) in Iguazu Falls, Brazil, from March 12-15. The company will showcase four presentations highlighting its respiratory syncytial virus (RSV) program:

The main oral presentation will feature results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, scheduled for March 14. A late-breaker poster will present data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for RSV treatment in young children.

Two additional poster presentations will focus on: (1) distinctions among fusion, N, and L inhibitors regarding preclinical antiviral effect and resistance profiles, and (2) PK and PK/PD results from the EDP-323 Phase 2 human challenge study. All presentations will be delivered at the Bourbon Cataratas do Iguazu venue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for Q1 FY2025 ended December 31, 2024. Total revenue was $17.0 million, down from $18.0 million in Q1 FY2024, consisting of royalties from MAVYRET®/MAVIRET® sales. The company reported a net loss of $22.3 million ($1.05 per share), compared to a $33.4 million loss ($1.58 per share) in the prior year.

Research and development expenses decreased to $27.7 million from $36.4 million, while G&A expenses reduced to $12.8 million from $16.5 million. The company maintains a strong financial position with $216.7 million in cash and marketable securities, expected to fund operations into fiscal 2028.

Key developments include ongoing recruitment for the RSVHR Phase 2 study of zelicapavir, with topline data expected in Q3 2025, and advancement of immunology portfolio including KIT inhibitor EPS-1421 and STAT6 program development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that its President and CEO, Jay R. Luly, Ph.D., will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2024, at 8:15 a.m. PT in San Francisco, CA.

The clinical-stage biotechnology company, which focuses on developing small molecule drugs for virology and immunology indications, will provide a live webcast of the presentation through the "Events and Presentations" section on the "Investors" page of their website. The webcast recording will remain available for a minimum of 30 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
conferences
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced that the United States District Court of Massachusetts has ruled against them in a patent infringement lawsuit against Pfizer. The Court granted Pfizer's summary judgment motion, declaring Enanta's '953 Patent invalid. This patent was related to Pfizer's COVID-19 antiviral, Paxlovid.

The Court also denied Enanta's partial motion for summary judgment of infringement. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit. Despite the ruling, the company maintains its commitment not to impede Paxlovid's production, sale, or distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
Rhea-AI Summary

Enanta Pharmaceuticals announced positive topline results from its first-in-pediatrics Phase 2 study of zelicapavir for treating respiratory syncytial virus (RSV) in children aged 28 days to 36 months. The study demonstrated significant antiviral effects with a 1.4 log decline in viral load at Day 5 compared to placebo in Part 2. A prespecified analysis of patients treated within 3 days of symptom onset showed a 1.2 log decline in viral load.

The study involved 96 patients (70 receiving zelicapavir, 26 placebo) across two parts. Zelicapavir demonstrated a favorable safety profile with no adverse events leading to treatment discontinuation. The drug achieved target exposure levels across all age groups, with doses of 5 mg/kg for ages ≥28 days to <12 months and 7.5 mg/kg for ages ≥12 months to ≤36 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.75%
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, December 9 at 8:30 a.m. ET. The event will present topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in children with respiratory syncytial virus (RSV). The study focused on both hospitalized and non-hospitalized children aged 28 days to 36 months.

The live webcast will be accessible through the company's website under the 'Events & Presentations' section in the investors area. Participants joining by phone are advised to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on Enanta's website for approximately 30 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.75%
Tags
conferences clinical trial
-
Rhea-AI Summary

Enanta Pharmaceuticals reported financial results for Q4 and fiscal year 2024. Total revenue was $14.6M for Q4 and $67.6M for FY2024, down from $18.9M and $79.2M respectively in 2023, due to declining MAVYRET®/MAVIRET® sales. Net loss was $28.8M ($1.36 per share) in Q4 and $116.0M ($5.48 per share) for FY2024.

The company announced positive Phase 2a results for EDP-323 in RSV treatment and expanded its immunology portfolio with a new STAT6 inhibition program and EPS-1421 development candidate. Cash position stands at $248.2M, expected to fund operations into fiscal 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
Rhea-AI Summary

Enanta Pharmaceuticals announced positive topline results from a Phase 2a human challenge study of EDP-323, a novel L-protein inhibitor for RSV treatment. The study demonstrated:

- 85-87% reduction in viral load AUC by qRT-PCR (p<0.0001)
- 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001)
- 66-78% reduction of total clinical symptoms score AUC (p<0.0001)

EDP-323 showed a favorable safety profile and pharmacokinetics supporting once-daily dosing. The drug achieved rapid and sustained antiviral effects, with results among the strongest reported in an RSV challenge study. Enanta aims to develop EDP-323 as a safe, effective oral treatment for RSV, addressing a substantial unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
Enanta Pharmaceuticals Inc

Nasdaq:ENTA

ENTA Rankings

ENTA Stock Data

108.80M
19.90M
6.58%
96.11%
12.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN